N-terminal pro-brain natriuretic peptide and risk of cardiovascular events in older patients with type 2 diabetes: the Edinburgh Type 2 Diabetes Study

Abstract

Aims/hypothesis The aim of this study was to investigate the association of N-terminal pro-brain natriuretic peptide (NTproBNP) with traditional cardiovascular risk factors and incident cardiovascular events in older people with type 2 diabetes. Methods In the prospective phase of the Edinburgh Type 2 Diabetes Study, 1066 men and women aged 60 to 75 years with type 2 diabetes mellitus were followed for 4 years; 112 participants had an incident cardiovascular event. At baseline, cardiovascular risk factors, pre-existing cardiovascular disease and levels of NT-proBNP were evaluated. Results Raised plasma NT-proBNP levels were associated with these classical cardiovascular risk factors: increased duration of diabetes, use of insulin, raised BMI, reduced HDLcholesterol, reduced renal function and use of lipid-lowering and anti-hypertensive medication (all p < 0.05). In the prospective analysis, NT-proBNP was strongly associated with subsequent risk of all cardiovascular disease events (HR per one SD increase in NT-proBNP 1.39; 95% CI 1.10, 1.75), independent of cardiovascular risk factors traditionally used to predict vascular events. NT-proBNP was also independently associated with incident coronary artery disease events (1.48, 95% CI 1.10, 1.98). The addition of NTproBNP to multivariate models improved the C-index by 0.019 for the 'hard' cardiac endpoint (fatal and non-fatal myocardial infarction). Conclusions/interpretation In older people with type 2 diabetes, NT-proBNP is associated with the development of coronary and cerebrovascular events, independent of a wide range of other vascular and metabolic risk factors, and may prove a useful addition to current vascular risk scores in diabetes populations.

Use of Vascular Assessments and Novel Biomarkers to Predict Cardiovascular Events in Type 2 Diabetes: The SUMMIT VIP Study

“…13,14 Notably, NT-proBNP only predicted CV events in 7 subjects with established CVD in the present study, irrespective of diabetes status. Other studies have identified elevated NT-proBNP as a CV risk factor in subjects with T2DM, 15 but to our knowledge it has previously not been shown that this primarily is the case for T2DM subjects with prevalent CVD. Subjects without diabetes that suffered a new event had increased carotid bulb IMT at baseline, but there was no difference in CCA IMT, total carotid plaque area or ABPI.…”

ANGPTL2 is associated with an increased risk of cardiovascular events and death in diabetic patients

“…In addition to established risk factors, several biomarkers associated with atherosclerosis, inflammation and congestive heart failure [6][7][8][9][10][11] have recently been proposed to improve risk stratification in type 2 diabetes mellitus patients. Promising data have been obtained using biomarkers associated with the closely interlinked processes of atherosclerosis and low-grade systemic inflammation [12].…”

Risk prediction of major complications in individuals with diabetes: the Atherosclerosis Risk in Communities Study

“…Although very few risk scores have included HbA1c in their risk prediction algorithm, even fewer have comprehensively evaluated and compared a panel of traditional and non‐traditional biomarkers of hyperglycaemia, cardiac damage, kidney filtration, liver function or inflammation . The biomarkers evaluated in the present study were selected because they are markers of physiological damage in the pathway to the clinical endpoints that we included, and have been associated with increased risk of complications in people with diabetes . Our model extends the findings of a previous ARIC study that developed a risk score for 10‐year prediction of a single endpoint of CHD in people with diabetes.…”